Ingenol esters induce apoptosis in Jurkat cells through an AP-1 and NF-κB independent pathway  by Blanco-Molina, Magdalena et al.
Research Paper
Ingenol esters induce apoptosis in Jurkat cells through an AP-1 and
NF-UB independent pathway
Magdalena Blanco-Molina a; *, Gian Cesare Tron b, Antonio Macho a,
Concepcio¤n Lucena a, Marco A. Calzado a, Eduardo Mun‹oz a, Giovanni Appendino b
aDepartamento de Biolog|¤a Celular, Fisiolog|¤a e Inmunolog|¤a, Universidad de Co¤rdoba, Avda. de Mene¤ndez Pidal s/n, 14004 Co¤rdoba, Spain
bDiSCAFF, Viale Ferrucci 33, 28100 Novara, Italy
Received 11 January 2001; revisions requested 27 February 2001; revisions received 20 April 2001; accepted 31 May 2001
First published online 26 June 2001
Abstract
Background: Ingenol derivatives have received constant and
multidisciplinary attention on account of their pleiotropic pattern
of biological activity. This includes activation of protein kinase C
(PKC), tumour-promotion, anticancer, and anti-HIV properties,
and the possibility of dissecting co-cancerogenic and clinically
useful activities has been demonstrated. Certain ingenol esters
show powerful anticancer activity, and a structure^activity
relationship model to discriminate between their apoptotic and
non-apoptotic properties has been developed.
Results : The polyhydroxylated southern region of ingenol was
selectively modified, using the anticancer and PKC activator
ingenol 3,20-dibenzoate (IDB) as a lead compound. The evalua-
tion of IDB analogues in apoptosis assays showed strict structure^
activity relationships, benzoylation of the 20-hydroxyl being
required to trigger apoptosis through a pathway involving
caspase-3 and occurring at the specific cell cycle checkpoint that
controls the S^M phase transition. Conversely, a study on the
activation of the PKC-dependent transcription factors AP-1 and
NF-UB by IDB analogues showed significant molecular flexibility,
including tolerance to changes at the 3- and 20-hydroxyls. IDB-
induced apoptosis was independent of activation of PKC, since it
was not affected by treatment with the non-isoform-selective PKC
inhibitor GF 109230X0.
Conclusions: Remarkable deviations from the tumour-promo-
tion pharmacophore were observed for both the apoptotic and the
PKC-activating properties of IDB analogues, showing that
ingenol is a viable template to selectively target crucial pathways
involved in tumour promotion and development. Since the
apoptotic and the PKC-activating properties of ingenoids are
mediated by different pathways and governed by distinct
structure^activity relationships, it is possible to dissect them by
suitable chemical modification. In this context, the esterification
pattern of the 5- and 20-hydroxyls is critical. ß 2001 Elsevier
Science Ltd. All rights reserved.
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1. Introduction
The use of spurges (Euphorbia spp.) to treat tumours is
well documented in Greek and Roman medical literature
[1], and modern studies have shown that these plants are
still employed to treat cancerous conditions in traditional
medicine in many areas of the world [1]. These historical
and ethnobotanical clues have been backed up by the dis-
covery of the powerful antineoplastic activity of ingenol
3,20-dibenzoate (IDB) [2], and certain semi-synthetic in-
genoids are among the most powerful cytotoxic agents
known, with an IC50 in the sub-nanomolar range [3]. Tu-
mour promotion [4], skin irritancy [5,6], protein kinase C
(PKC) activation [7,8], VCAM-1 inhibition [9], nerve
growth factor promotion [10], as well as pro-in£ammatory
[4,11], molluscicide [12], and antiviral activities [13] have
also been documented for ingenoids, testifying to the rele-
vance of this class of diterpenoids for biomedical research.
A pleiotropic pattern of activity is not uncommon for
tumour promoters. Nevertheless, a clear separation be-
tween co-cancerogenic and clinically useful activities has
been observed for ingenoids [13,14], validating the parent
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polyol as a versatile template for the induction/modulation
of bioactivity. Not unexpectedly, ingenol has also received
constant attention within the synthetic community [15],
although its total synthesis is yet to be achieved.
Ingenol esters can display both co-carcinogenic and
antitumour activity [16], and IDB, the archetypal antitu-
mour ingenoid, can indeed activate responses mediated by
PKC [7,8,17], the main target of tumour-promoting phor-
boid esters. However, while IDB shows in£ammatory ac-
tivity comparable to that of phorbol esters, it only retains
a marginal fraction of their tumour-promoting activity [7],
and similar di¡erences were observed in other pairs of
ingenol 3- and 3,20-diesters [7]. The mechanism underlying
this paradoxical behaviour is largely unknown, as are the
critical structural features responsible for the dissection of
the co-carcinogenic and the antitumour activities. These
¢ndings underscore our limited knowledge of the ingenoid
pharmacophore, while the cell type-dependent role of
PKC adds an additional layer of complexity to this issue.
Thus, while IDB induces apoptosis in thymocytes through
a PKC-independent pathway [17], PKC activation by
phorbol esters is crucial to activate the apoptotic machi-
nery in other cell types [18].
PKC consists of several subfamilies of serine/threonine-
speci¢c protein kinases [19], Ca2-dependent classical
PKC (cPKC: K, L1, L2 and Q), Ca2-independent novel
PKC (nPKC: N, O, R and a) and atypical PKC (aPKC:
M, S, h), which play a central role in signal transduction in
eukaryotes [20^22]. Some of their molecular targets are
transcription factors which regulate gene expression,
such as the activator protein-1 (AP-1) and the nuclear
factor UB (NF-UB), both involved in the regulation of
cell proliferation and apoptosis [23,24].
The evaluation of IDB analogues modi¢ed at C-20 has
shown that cytotoxicity and PKC activation can be dis-
sected [25], and similar results were reported regarding the
anti-HIV activity and PKC activation properties of phor-
bol esters [26]. These ¢ndings have rekindled interest in
phorboids as drug leads, encouraging mechanistic studies
on their anticancer and apoptotic activities. We report
here that di¡erent pathways, critically dependent on the
oxygenation pattern at C-5 and C-20, mediate the apopto-
tic and PKC-activating properties of IDB.
2. Results
2.1. Ingenol 20-benzoates induce apoptosis in Jurkat cells
The polyhydroxylated southern region plays a key role
in the biological activity of ingenoids [25,33,34]. The apo-
ptotic activity of the parent polyol (1), IDB (2), and ana-
logues variously substituted at C-3, C-5 and C-20 (com-
pounds 3^7, Fig. 1) was investigated in the leukaemia
Jurkat cell line. The cells were incubated with 10 WM con-
centration of each compound for 48 h, and the hypodi-
ploidy (i.e., loss of fragmented DNA) was detected, using
propidium iodide (PI) staining as a marker for apoptosis.
Fig. 1. Chemical structures of 1 (ingenol), 2 (ingenol 3,20-dibenzoate), 3 (ingenol 20-benzoate), 4 (ingenol 3-benzoate), 5 (20-deoxy-20-£uoroingenol),
6 (20-deoxy-20-£uoroingenol 3-benzoate), 7 (20-deoxy-20-£uoroingenol 3,5-dibenzoate), 8 (ingenol 20-benzoate 3,4-carbonate) ; 9 (ingenol 20-benzoate
3,4-thiocarbonate).
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Fig. 2A shows that only 2 and 3 were able to induce a
strong increase in the percentage of hypodiploid cells
(61.3% and 71.3% respectively). Within the series investi-
gated, these are the only compounds where the 20-hydrox-
yl is benzoylated. The apoptosis induced by these two
compounds was dose-dependent, and concentrations rang-
ing from 0.1 to 30 WM mediated a progressive increase in
the percentage of subdiploid cells after 24 h of culture.
In contrast, ingenol itself (1) did not induce signi¢cant
apoptosis even at the higher doses (Fig. 2B). Since
apoptosis can also be detected after 24 h of treatment,
doses of 10 WM and 24 h treatment were generally used
throughout.
2.2. Apoptosis induced by IDB in Jurkat cells is mediated
by caspase-3 activation and occurs mainly at the
S phase of the cell cycle
The caspase family consists of postaspartate-cleaving
cysteine proteases which have been shown to be required
for apoptosis in a number of experimental systems [35,36].
To establish the involvement of caspases in IDB-mediated
apoptosis of Jurkat cells, we preincubated the cells with
the tetrapeptide caspase inhibitors Ac-DEVD-cmk or Z-
YVAD-cmk before IDB treatment. Z-YVAD-cmk, which
was reported to speci¢cally inhibit caspase-1 and related
enzymes, had a limited e¡ect on the increase in the per-
Fig. 2. Induction of apoptosis in Jurkat cells treated with ingenol and derivatives. (A) Jurkat cells were treated with a concentration of 10 WM of the
compounds for 48 h, and the cell cycle was analysed by PI staining. Bars indicate the percentage of subdiploid cells (DNA-fragmented cells). (B) Hypo-
diploidy induced by ingenols is dose-dependent. Jurkat cells were treated with the indicated concentrations of ingenols 1, 2 (IDB) and 3 for 24 h and
the cell cycle was analysed as above. Values are means þ S.D. of three independent experiments.
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centage of subdiploid cells induced by IDB (10 WM). In
contrast, the same dose of Ac-DEVD-cmk, which is more
speci¢c for the inhibition of caspase-3, a member of the
CED-3 subfamily of caspases, was an e¡ective inhibitor of
apoptosis induced by IDB.
The involvement of cell cycle control in apoptosis in-
duced by IDB in Jurkat cells was studied by double stain-
ing with PI and FITC-4-deoxy-2-uridine triphosphate
(FITC-dUTP) as described in Section 5. This gives infor-
mation on the cell cycle phase where DNA fragmentation
occurs. Fig. 3B shows that most DNA fragmentation was
detected in the S phase of the cell cycle in Jurkat cells
treated for 24 h with IDB at 10 WM concentration. A small
but signi¢cant percentage of cells undergoing DNA frag-
mentation at both G0/G1 and M phases of the cell cycle
was also detected.
2.3. Activation of the AP-1 and NF-UB transcription
factors by ingenol and its esters
In order to study the role of ingenoids in the activation
of PKC-inducible transcriptions factors, we stimulated
Jurkat cells with IDB (10 WM) for 3 h and nuclear extract
was obtained and analysed by electrophoretic mobility
shift assay (EMSA) using an AP-1-speci¢c 32P-labelled
oligonucleotide. In Fig. 4A we show that IDB increased
the binding of AP-1 to DNA and that it was completely
abolished by a 100-fold concentration of cold AP-1 oligo-
nucleotide in the binding reaction, but not by the presence
of irrelevant oligonucleotides (NF-UB and SP-1). Next, we
stimulated Jurkat cells either with phorbol myristate ace-
tate (PMA, 50 ng/ml) or with increasing doses of ingenols
1, IDB, 3, 5 and 6 for 3 h as indicated, and nuclear ex-
tracts were obtained and analysed by EMSA. As shown in
Fig. 4B, although to a di¡erent extent, all compounds
increased the AP-1 binding to DNA. To correlate these
results with transcriptional activities, Jurkat and HeLa
cells were transiently co-transfected with equimolar con-
centrations of both RSV-L-Gal and AP-1-Luc plasmids.
Twenty-four hours after transfection, cells were treated
with PMA or ingenols 1 and IDB for 6 h, and transacti-
vation was determined and expressed as fold induction.
Fig. 4C shows that both compounds were e¡ective in the
induction of AP-1 transactivation in both cell lines, IDB
being more potent than the parent polyol, as expected
from the binding data. In order to evaluate whether an-
other inducible transcription factor had also been acti-
vated by ingenols, we carried out kinetics experiments in
Jurkat cells stimulated with either IDB, ingenol 1 or in-
genol 5 (10 WM each), and in Fig. 5A it is shown that all
Fig. 3. (A) The caspase-3 inhibitor Ac-DEVD-cmk inhibits IDB-induced apoptosis. Jurkat cells were treated with IDB (10 WM) in the presence or ab-
sence of the caspase-1 inhibitor Z-YVAD-cmk (100 WM) and the caspase-3 inhibitor Ac-DEVD-cmk (100 WM) for 24 h, and the percentage of subdi-
ploid cells was detected using £ow cytometry. (B) S^M phase dependence for apoptosis induced by IDB. Jurkat cells were stimulated with IDB (10
WM) for 24 h and the cell cycle and the DNA strand breaks analysed by the TUNEL method using £ow cytometry. Results are representative of three
independent experiments.
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ingenols tested induced an increase in the binding of NF-
UB in nuclear extracts from stimulated Jurkat cells. The
speci¢city of the binding was studied by supershift and
cold competition experiments, and we identi¢ed that the
heterodimer p50/p65 is the main complex activated by in-
genols in Jurkat cells. The NF-UB binding results correlate
well with the transactivation experiments performed in
HeLa cells, where we found that IDB was more potent
than either ingenol 1 or 5 to transactivate the KBF-Luc
reporter plasmid (Fig. 5B). Altogether, these results show
that both pro-apoptotic and non-apoptotic ingenoids can
activate the AP-1 and the NF-UB transcription factors.
2.4. PKC is not involved in the apoptotic activity of IDB
IDB can activate several isoforms of PKC in both lym-
phoid and non-lymphoid cells [8,17^18]. Thus, to study
whether this enzyme is involved in NF-UB activation and
apoptosis, we transfected HeLa cells with the KBF-Luc
plasmid. Twenty-four hours after transfection, the cells
were stimulated for 6 h with PMA (10 ng/ml), ingenol
(1) (10 WM) or IDB (10 WM) in the presence or absence
of GF109203X (0.01 WM), a non-isoform-selective PKC
inhibitor [37]. GF109203X completely inhibited NF-UB
transactivation induced by PMA, ingenol and IDB (Fig.
6A). Similarly, this inhibitor prevented the binding of NF-
UB to DNA in Jurkat cells stimulated with IDB (10 WM)
for 90 min (Fig. 6B).
Next, we studied if the inhibition of PKC by
GF109203X could a¡ect the apoptosis induced by IDB
in Jurkat cells. Fig. 6C shows that apoptosis induced by
IDB was not mediated by PKC activation, since the PKC
inhibitor did not reduce the percentage of hypodiploid
cells observed after 18 h stimulation with a pro-apoptotic
concentration of IDB; rather, it increased the apoptosis
induced by IDB.
2.5. Activation of NF-UB and AP-1 by ingenoids requires a
free hydroxyl at C-5
In our set of ingenoids, modi¢cations of the 20-hydroxyl
do not a¡ect the capacity to activate NF-UB and AP-1
transcription factors. On the other hand, the apoptotic
activity depends on the modi¢cation of this position, since
only 2 (IDB) and 3 are pro-apoptotic. To investigate the
role of the 5-hydroxyl on the transcriptional activities of
ingenoids, the non-apoptotic compound 7, where the 5-hy-
droxyl is esteri¢ed with benzoic acid and the 20-hydroxyl
is replaced by a £uorine to prevent acylotropic migration
from the 5- to the 20-hydroxyl, was investigated. Thus,
Jurkat cells were stimulated with either PMA or increasing
doses of 7 for 3 h, and nuclear extracts studied for DNA
Fig. 4. Activation of AP-1 by ingenols. (A) Nuclear extracts were prepared from Jurkat cells treated with IDB (10 WM) for 3 h and the binding of AP-
1 to DNA was performed with a 32P end-labelled AP-1-speci¢c double-stranded oligonucleotide in the presence or absence of a 50-fold excess of cold
AP-1, NF-UB and SP-1 oligonucleotides. (B) Jurkat cells were stimulated with phorbol myristate acetate (PMA, 50 ng/ml) and the indicated concentra-
tions of ingenols 1, 2 (IDB), 3, 5 and 6 for 3 h, and the binding of AP-1 was done as described above. The result for ingenol 6 is a shorter exposure
of a retardation gel from a separate experiment. (C) Induction of AP-1 transcriptional activity by ingenols. Jurkat and HeLa cells were transiently co-
transfected with equimolar concentrations of the plasmids RSV-LGal and AP-1-Luc, and 24 h later stimulated with di¡erent concentrations of IDB and
ingenol 1 or with PMA (50 ng/ml). After 6 h stimulation, the cells were lysed and the luciferase activity measured and represented as fold induction
after normalisation with the measure of L-Gal activity. Values are means þ S.D. of three independent experiments in each cell line.
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binding of NF-UB and AP-1. Fig. 7A shows that, unlike
its 5-debenzoyl derivative, 7 does not activate NF-UB
binding and it is a very weak activator of AP-1. To com-
pare the lack of binding of NF-UB and AP-1 with the
transcriptional activity, the e¡ect of the selected com-
pounds was investigated in the K562-AIM cell line, which
contains the luciferase gene driven by the activation im-
mediate marker (AIM/CD69) gene promoter stably trans-
fected [38]. This promoter is highly responsive to NF-UB
and AP-1 transcription factors [38]. Thus, K562-AIM cells
were stimulated with either PMA (10 ng/ml), ingenol 3,
IDB (2) or ingenol 7 (10 WM) for 6 h, and we measured
the luciferase activity as described above. As expected,
IDB and 3 were as e¡ective as PMA to transactivate the
AIM promoter, while 7 was practically inactive in this
assay. Taken together, these results suggest that the 5-hy-
droxyl is critical for PKC activation by IDB and its ana-
logues.
2.6. Hydroxylation at C-3 and C-4 is not required for
apoptosis and NF-UB activation
The esteri¢cation of the 3-hydroxyl with lipophilic acids
is essential for tumour promotion by ingenol esters. To
evaluate the role of the hydroxyl groups at C-3 and C-4
in the apoptotic activity, the cyclic carbonate 8 and thio-
carbonate 9 were synthesised (Fig. 1). Jurkat cells were
treated with these compounds (10 WM) for 24 h and the
induction of apoptosis determined by £ow cytometry. Fig.
8A shows that both ingenols induce apoptosis in Jurkat
cells to a similar extent, as measured by the percentage of
hypodiploid cells (33.6 vs. 37.8%, respectively). Moreover,
when NF-UB activation was evaluated in transiently trans-
fected HeLa cells, both compounds were equally potent to
activate the NF-UB reported gene (Fig. 8B). These results
reinforce the hypothesis that benzoylation at position C-20
is required for ingenol-induced apoptosis.
Fig. 5. Induction of NF-UB by ingenols. (A) Jurkat cells were treated with IDB (2), ingenol 1 and 5 (10 WM) for the indicated times, and the binding
of NF-UB to DNA in nuclear extract was analysed by EMSA. The binding speci¢city of NF-UB was studied by supershift with speci¢c antiserum and
cold competition. (B) HeLa cells were transiently co-transfected with equimolar concentrations of the plasmids RSV-LGal and KBF-Luc and 24 h later
stimulated with IDB, ingenol 1 and 5 (10 WM) or with PMA (50 ng/ml). After 6 h stimulation, the cells were lysed and the transcriptional activity rep-
resented as indicated in Fig. 4.
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3. Discussion
Despite the variety of biological end-points of ingen-
oids, clear structure^activity relationships have emerged
only as regards tumour promotion, which requires the
presence of a lipophilic ester group at C-3 and a free
hydroxyl at C-20 [11]. A binding model based on a
three-fold interaction with PKC mediated by the 3-ester
carbonyl, the 9-keto group, and the 20-hydroxyl has
emerged [39,40]. However, the biological activity of the
parent polyol and that of several 3,20-diesters suggests
that alternative ¢ts to PKC exist [4], while large di¡erences
in binding between simpli¢ed analogues and the natural
derivatives [41] underscore the relevance of structural ele-
ments di¡erent from those highlighted by the postulated
pharmacophore for PKC interaction.
Within the set of compounds investigated, only those
bearing a benzoate at C-20 (compounds 2, 3, 8, 9) could
induce apoptosis in Jurkat cells. The lack of activity of
ingenol 3-benzoate (4) showed that the induction of apo-
ptosis by IDB could not be mediated by enzymatic loss of
the 20-ester group, which would generate an inactive com-
pound. Moreover, the activity of IDB, ingenol 20-ben-
zoate (3), ingenol 3,4-carbonate 20-benzoate (8), and in-
genol 3,4-thiocarbonate 20-benzoate (9) shows that the
induction of apoptosis is relatively insensitive to changes
at C-3, a substantial and dramatic deviation from the tu-
mour-promotion pharmacophore.
Deviation from the tumour-promotion pharmacophore
was also evidenced as regards PKC-mediated NF-UB and
AP-1 activation. Although we have not measured directly
the translocation and activation of nPKC, the activation
of both transcription factors through nPKC has been
documented. Thus, in the AP-1 binding assays the 20-de-
oxy-20-£uoro derivatives 5 and 6 showed an activity com-
parable to that of their corresponding hydroxylated com-
pounds (1 and 4, respectively), while the 20-esters 2 and 3
were active, as were 8 and 9, where the 3-hydroxyl was
Fig. 6. The PKC inhibitor GF109203X prevents NF-UB from binding to DNA induced by IDB and the transcriptional activity of NF-UB induced by
ingenol (1) and IDB (2). (A) Jurkat cells were stimulated with 10 WM of IDB for 90 min in the presence or absence of the PKC inhibitor (a section of
the EMSA gel is shown). (B) HeLa cells were transiently transfected with the KBF-luc plasmid, and 24 h later stimulated for 6 h with PMA (50 ng/
ml), 1 (10 WM) or 2 (10 WM) in the presence or absence of the PKC inhibitor (0.02 WM). (C) GF109203X does not a¡ect IDB-induced apoptosis. Jurkat
cells were treated with IDB (10 WM) with or without the PKC inhibitor (0.02 WM) and cell cycle analyses performed by PI staining and £ow cytometry.
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part of a carbonate (8) or a thiocarbonate ring (9). Inter-
estingly, benzoylation of the 5-hydroxyl of the 20-deoxy-
20-£uoro derivative 7 led to a dramatic decrease of activ-
ity, suggesting that the 5-hydroxyl is critical for PKC
binding underlying both AP-1 and NF-UB activation.
The a⁄nity of IDB for PKC was quanti¢ed by inhibi-
tion of [3H]PDBU binding to PKC-K, which only showed
a modest activity [41]. To explain the exceedingly high
in£ammatory activity of this compound, in vivo enzymatic
hydrolysis to the corresponding 3-monobenzoate, a highly
irritant activator of cPKC, was suggested [41]. However,
the lack of evidence for the in vivo hydrolysis of the 20-
ester group, the di¡erent pro¢le of tumour-promoting ac-
tivity of IDB and ingenol-3-benzoate, as well as recent
data from the study of calcium-independent induction of
apoptosis in thymocytes [17], suggested that IDB targets
those PKC isoforms di¡erent from cPKC isoforms. Thus,
IDB was identi¢ed as a selective activator of PKC-O,
although further studies have demonstrated that IDB
can interact with almost all isoforms of novel PKC [17].
Since these nPKCs do not require calcium for activation,
the observation that neither IDB nor ingenol 3-benzoate
mobilises calcium intracellularly (data not shown) further
supports the view that non-classical PKCs mediate the
activation of NF-UB and AP-1 transcription factors by
these compounds.
Apoptosis induced by ingenoid 20-benzoate depends on
the activation of caspase-3, and occurs mainly at the S
phase of the cell cycle. The discovery of di¡erent struc-
ture^activity relationships for apoptotic and PKC-medi-
ated responses suggests that the two processes are mecha-
nistically distinct. In accordance with this, the PKC
inhibitor GF109203X does not reduce hypodiploidy in-
duced by IDB; rather, it increased the apoptosis induced
by IDB, showing that PKC activation may be involved in
the anti-apoptotic activity. This is consistent with the fact
that PKC activation in Jurkat cells makes them resistant
to apoptosis induced by the death receptor FAS [42].
Thus, depending on the cell type, non-apoptotic PKC-
binding ingenoids can behave as tumour promoters in at
least two ways: either by activating a set of PKC-depen-
dent genes involved in cellular growth and di¡erentiation,
or, alternatively, by rendering the cells resistant to apopto-
sis mediated by the death receptor Fas/APO-1 and by NF-
UB-dependent anti-apoptotic genes [43^45].
Phorboid-containing plants have been used to treat tu-
mours for centuries [1], and PMA, the archetypal tumour-
promoting phorboid, has been clinically investigated as an
anticancer agent [46]. It is therefore ironic that most stud-
ies on these essential probes for cell biology have been
focused instead on their skin-irritant and tumour-promot-
ing activities. The discovery that the apoptotic and the
PKC-activating properties of IDB are mediated by di¡er-
ent pathways and governed by distinct structure^activity
relationships should foster investigations aimed at a better
mechanistic understanding of the anticancer potential of
phorboids. In this context, the identi¢cation of the molec-
ular targets underlying their antitumour activity and the
dissection of anticancer and PKC-mediated activities by
suitable structural modi¢cations will be essential to obtain
Fig. 7. (A) 20-Deoxy-20-£uoroingenol-3,5-dibenzoate (7) does not activate NF-UB or AP-1 binding to DNA in Jurkat cells. (B) Ingenol (1) and IDB
(2), but not 7, stimulate AIM gene transcription in K562 cells.
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non-pleiotropic drug candidates amenable to pharmaceut-
ical development.
4. Signi¢cance
Ingenoids are a structurally diverse class of diterpenes
endowed with a pleiotropic pattern of biological activity
and paradoxical tumour-promoting and anticancer prop-
erties. The polyhydroxylated southern region has a key
role in the biological activity of these compounds, and
we have developed a structure^activity relationship model
to evaluate the apoptotic and the non-apoptotic properties
of ingenoids. The induction of apoptosis and the activa-
tion of the PKC-dependent transcription factors NF-UB
and AP-1 turned out to be mediated by di¡erent signal
pathways. Esteri¢cation of the 20-hydroxyl was required
to induce apoptosis, while a free 5-hydroxyl was critical
for PKC activation, evidencing signi¢cant deviations from
the tumour-promotion pharmacophore for both activities.
The ¢nding that the apoptotic and the PKC-activating
properties of IDB are mediated by di¡erent pathways
and governed by distinct structure^activity relationships
validates ingenol as a lead structure to develop new anti-
cancer drugs.
5. Materials and methods
5.1. Cell lines and reagents
Jurkat cells (ATCC, Rockville, MD, USA) were maintained in
exponential growth in RPMI 840 medium (Bio-Whittaker, Ver-
viers, Belgium) and the cervix cancer HeLa cells (ATCC) in Dul-
becco’s modi¢ed Eagle’s medium (Bio-Whittaker). The culture
media were supplemented with 10% heat-inactivated foetal calf
serum, 2 mM L-glutamine and the antibiotics penicillin and strep-
Fig. 8. Carbonatation and thiocarbonatation of ingenol 20-benzoate do not a¡ect its biological activities. (A) Jurkat cells were treated with a concentra-
tion of 10 WM of the compounds for 24 h, and the cell cycle was analysed by PI staining. Bars indicate the percentage of subdiploid cells (DNA-frag-
mented cells). (B) HeLa cells were transiently transfected with an NF-UB-dependent luciferase reporter plasmid, and 24 h later stimulated with ingenols
1, 8 and 9 at the indicated concentration. After 6 h stimulation, the cells were lysed and the luciferase activity measured. The transcriptional activity
was expressed as fold induction. Values are means þ S.D. of two independent experiments.
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tomycin (Gibco, Paisley, UK). K562-AIM cells were maintained
in complete RPMI medium containing G418 (100 Wg/ml).
[Q-32P]ATP (3000 Ci/mM) was purchased from ICN (Costa
Mesa, CA, USA). The cell-permeable inhibitors of caspase-1
(Z-YVAD-cmk) and caspase-3 (Ac-DEVD-cmk) were from Bach-
em (Switzerland). FITC-dUTP and terminal deoxynucleotide
transferase (TdT) were from Boehringer Mannheim (Germany).
The PKC inhibitor GF109203X was from Biomol (Plymouth
Meeting, PA, USA). All other reagents not cited above or later
were from Sigma Chemical Co. (Barcelona, Spain). Ingenol was
obtained from the seeds of the caper spurge [27].
5.2. Synthesis of ingenoids
Compounds 2^7 are known, and were prepared according to
literature procedures [25,28]. Compounds 8 and 9 were synthe-
sised as follows (synthesis of 8 as representative) : they were
added to a cooled (0‡C) solution of ingenol 5,20-acetonide [28]
(100 mg, 1.26 mM) in dry CH2Cl2 (10 ml), pyridine (5 ml) and
excess phosgene (1.0 ml of a 20% toluene solution, 10 mM, 38
mol. equiv.). After being stirred at 0‡C for 30 min the reaction
was worked up by dilution with hexane^ether (3:1, 100 ml) and
sequential washing with water and brine. Removal of the solvent
gave the crude 3,4-carbonate 5,20-acetonide, which was taken up
in 10 ml of 1033 M methanolic HClO4. After being stirred for 45
min at room temperature, the reaction was worked up by the
addition of sat. aq. NaHCO3, concentration at reduced pressure
and partition between water and EtOAc. The organic phase was
washed with brine, dried (MgSO4) and evaporated, to give ingen-
ol 3,4-carbonate as a colourless foam. For the selective benzoy-
lation, the latter was dissolved in dry CH2Cl2 (1 ml), and the
cooled (318‡C) solution was treated with N-3-dimethylamino-
propyl-NP-ethylcarbodiimide hydrochloride (EDC, 74 mg, 0.39
mM), 4-dimethylaminopyridine (DMAP, 47 mg, 0.39 mM), and
benzoic acid (47 mg, 0.39 mM). The solution was stirred at
318‡C overnight and worked up by dilution with EtOAc and
sequential washing with 5% NaOH, water, and brine. After re-
moving the solvent, the crude product was puri¢ed by column
chromatography on silica gel (hexane^EtOAc 9:1 as eluant) to
give 66 mg (53% from ingenol 5,20-acetonide) 8 as a colourless
amorphous foam. [K]25D 335‡ (CH2Cl2, c 0.8); IR (Xmax, liquid
¢lm) cm31 : 3474, 1833, 1715, 1603, 1453, 1385, 1282, 1123, 1030;
1H NMR (400 MHz, CDCl3): N 8.00 (Bz-AAP), 7.58 (Bz-C), 7.44
(Bz-BBP), 6.29 (d, J = 4.8 Hz, H-7), 6.07 (s, H-1), 5.21 (s, H-3),
4.90 (d, J = 12.6 Hz, H-20a), 4.70 (d, J = 12.8 Hz, H-20b), 3.74
(m, H-8), 3.48 (s, H-5), 2.33 (m, H-11), 2.12 (m, H-12a), 1.91 (s,
H-19), 1.85 (m, H-12b), 1.13 (s, H-16), 1.06 (s, H-17), 0.96 (d,
J = 6.9 Hz, H-18), 0.87 (m, H-14), 0.74 (m, H-13). HRMS:
478.5342 (calc. for C28H30O7 : 478.5336). For the synthesis of 9,
thiocarbonyldiimidazole was substituted for phosgene, carrying
out the thiocarbonylation in re£uxing toluene for 90 min. The
overall yield from ingenol 5,20-acetonide was 34%. 9 was ob-
tained as a colourless oil, [K]25D 328‡ (CH2Cl2, c 0.6); IR (Xmax,
liquid ¢lm) cm31 : 3474, 1809, 1725, 1285, 1262, 1111, 1030, 655;
1H NMR (400 MHz, CDCl3): N 8.02 (Bz-AAP), 7.60 (Bz-C), 7.46
(Bz-BBP), 6.31 (d, J = 4.1 Hz, H-7), 6.12 (s, H-1), 5.48 (s, H-3),
5.03 (d, J = 12.8 Hz, H-20a), 4.76 (d, J = 12.8 Hz, H-20b), 4.05 (s,
H-5), 3.72 (m, H-8), 2.34 (m, H-11), 2.12 (m, H-12a), 1.94 (s, H-
19), 1.87 (m, H-12b), 1.18 (s, H-16), 1.09 (s, H-17), 1.00 (d, J = 6.8
Hz, H-18), 0.79 (m, H-13 and H-14). HRMS: 494.597 (calc. for
C28H30O6S: 494.6002).
5.3. Determination of nuclear DNA loss and cell cycle analysis
The percentage of cells undergoing chromatinolysis (subdiploid
cells) was determined by ethanol ¢xation (70%, for 24 h at 4‡C).
Then, the cells were washed twice with phosphate-bu¡ered saline
(PBS) containing 4% glucose and subjected to RNA digestion
(RNase A, 50 U/ml) and PI (20 Wg/ml) staining in PBS for 1 h
at room temperature. The cell cycle was analysed by cyto£uori-
metry as previously described [29]. With this method, low molec-
ular weight DNA leaks from the ethanol-¢xed apoptotic cells and
the subsequent staining make it possible to determine the percent-
age of subdiploid cells (sub-G0/G1 fraction).
5.4. Detection of DNA strand breaks by the TUNEL method
The percentage of apoptotic cells was alternatively measured
by the TUNEL method as previously described, with minor mod-
i¢cations. Brie£y, cells (1U106) were ¢xed in 4% paraformalde-
hyde in PBS for 24 h at 4‡C, washed twice in PBS and permea-
bilised in 0.1% sodium citrate containing 0.1% Triton X-100 for
2 min. Fixed cells were washed three times in PBS and resus-
pended in a ¢nal volume of 50 Wl of TUNEL bu¡er (0.3 nmol
FITC-dUTP, 3 nmol dATP, 50 nmol CoCl2, 5 U TdT, 200 mM
potassium cacodylate, 250 Wg/ml bovine serum albumin (BSA)
and 25 mM Tris^HCl pH 6.6). The cells were incubated for 1 h
at 37‡C and then washed twice in PBS and analysed by £ow
cytometry. To determine both the DNA strand breaks and the
cell cycle, TUNEL-stained cells were counterstained with PI and
treated with RNase as described above prior to cyto£uorimetric
analysis. In this method, ¢xation in formaldehyde prevents the
leaking of low molecular weight DNA from apoptotic cells, and
thus the cell cycle distribution estimates both apoptotic and non-
apoptotic cells [30].
5.5. Isolation of nuclear extracts and mobility shift assays
Jurkat cells were cultured at 2U106/ml and stimulated with the
agonists in complete medium as indicated. Cells were then
washed twice with cold PBS and proteins from nuclear extracts
isolated as previously described [31]. Protein concentration was
determined by the Bradford method (Bio-Rad, Richmond, CA,
USA). For the EMSA assay, the consensus oligonucleotide
probes: NF-UB, 5P-AGTTGAGGGGACTTTCCCAGG-3P ;
AP-1, 5P-CGCTTGATGAGTCAGCCGGAA-3P, were labelled
with [Q-32P]ATP (Amersham, Freiburg Germany). The binding
reaction mixture contained 3 Wg of nuclear extract, 0.5 Wg poly-
(dI-dC) (Pharmacia Fine Chemical, Piscataway, NJ, USA), 20
mM HEPES pH 7, 70 mM NaCl, 2 mM dithiothreitol (DTT),
0.01% NP-40, 100 Wg/ml BSA, 4% Ficoll, and 100 000 cpm of
end-labelled DNA fragments in a total volume of 20 Wl. When
indicated, 0.5 Wl of rabbit anti-p50, anti-p65 or preimmune serum
[32] was added to the standard reaction before the addition of the
radiolabelled probe. Dr. Alain Israe«l (Institut Pasteur, France)
kindly provided the anti-NF-UB sera. For cold competition, a
100-fold excess of the double-stranded oligonucleotide competitor
was added to the binding reaction. After 30 min incubation at
4‡C, the mixture was electrophoresed through a native 6% poly-
acrylamide gel containing 89 mM Tris^borate, 89 mM boric acid
and 1 mM EDTA. Gels were pre-electrophoresed for 30 min at
225 V and then for 2 h after loading the samples. These gels were
dried and exposed to XAR ¢lm at 380‡C.
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5.6. Transient transfections and luciferase activity
HeLa (105/ml) or Jurkat cells (2U106/ml) were transiently
transfected using either the lipofectamine reagent (Life Technol-
ogies, Madrid, Spain) or the Superfect reagent (Qiagen, Ger-
many) respectively, according to the manufacturer’s recommen-
dations. To determine AP-1-dependent transcription, Jurkat or
HeLa cells were transfected with the AP-1-Luc reporter plasmid
(0.5 Wg/ml) which was constructed by inserting three copies of an
SV40 AP-1 binding site into the Xho site of pGL-2 promoter
vector (Promega, Madison, WI, USA), and to determine NF-
UB-dependent transcription, HeLa cells were transfected with
the KBF-Luc (0.5 Wg/ml) reporter plasmid which contains three
copies of an NF-UB binding site (from the MHC promoter) fused
to a minimal SV40 promoter driving luciferase [32]. Twenty-four
hours after transfection the cells were stimulated with the indi-
cated agonists for 6 h and then lysed in 25 mM Tris^phosphate
pH 7.8, 8 mM MgCl2, 1 mM DTT, 1% Triton X-100, and
7% glycerol. Luciferase activity was measured in a luminometer
(Lumat Berthold, USA) following the instructions of the lucifer-
ase assay kit (Promega). The background obtained with the lysis
bu¡er was subtracted in each experimental value. All the experi-
ments were repeated at least three times. Transfection e⁄ciencies
were normalised by co-transfection with the L-galactosidase ex-
pression plasmid RSV-L-galactosidase, and L-galactosidase levels
were determined using a commercial kit (Promega).
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